The9 Stock Forecast, Price & News

Wall Street analysts have given The9 a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but The9 wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

The9 saw a increase in short interest in July. As of July 30th, there was short interest totaling 1,190,000 shares, an increase of 14.4% from the July 15th total of 1,040,000 shares. Based on an average daily volume of 3,150,000 shares, the short-interest ratio is presently 0.4 days. Approximately 10.5% of the shares of the stock are sold short.
View The9's Short Interest.

The9's stock was trading at $6.3870 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NCTY stock has increased by 89.6% and is now trading at $12.11.
View which stocks have been most impacted by COVID-19.

Shares of The9 reverse split on Monday, October 19th 2020. The 1-10 reverse split was announced on Tuesday, October 13th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 16th 2020. An investor that had 100 shares of The9 stock prior to the reverse split would have 10 shares after the split.

Some companies that are related to The9 include Viad (VVI), Liquidity Services (LQDT), Rimini Street (RMNI), MoneyGram International (MGI), i3 Verticals (IIIV), Tabula Rasa HealthCare (TRHC), Blade Air Mobility (BLDE), Gravity (GRVY), Newtek Business Services (NEWT), International Money Express (IMXI), Cass Information Systems (CASS), QIWI (QIWI), Resources Connection (RGP), Dale Jarrett Racing Adventure (TVMD) and Advantage Solutions (ADV).
View all of NCTY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other The9 investors own include Amarin (AMRN), Gevo (GEVO), Biocept (BIOC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), Acasti Pharma (ACST), Anavex Life Sciences (AVXL), BIOLASE (BIOL), EyePoint Pharmaceuticals (EYPT) and Jaguar Health (JAGX).

The9 trades on the NASDAQ under the ticker symbol "NCTY."

The9's stock is owned by many different retail and institutional investors. Top institutional investors include Susquehanna International Group LLP (0.00%), Carmignac Gestion (0.56%), Citigroup Inc. (0.39%), Wolverine Trading LLC (0.00%), Citadel Advisors LLC (0.00%) and Cutler Group LP (0.00%).

NCTY stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.

NCTY stock was purchased by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP, Citigroup Inc., Paloma Partners Management Co, Morgan Stanley, Morgan Stanley, SG Americas Securities LLC, Wolverine Trading LLC, and Group One Trading L.P..

Shares of NCTY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NCTY stock can currently be purchased for approximately $12.11.

The9 has a market capitalization of $227.45 million and generates $100,000.00 in revenue each year.

The9 employs 105 workers across the globe.

The official website for The9 is www.the9.com.

The9 is headquartered at BUILDING NO.3 690 BIBO ROAD ZHANG JIANG HI-TECH PARK, SHANGHAI F4, 201203.

The9's mailing address is BUILDING NO.3 690 BIBO ROAD ZHANG JIANG HI-TECH PARK, SHANGHAI F4, 201203. The technology company can be reached via phone at 862161086080 or via email at [email protected]